Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Dow
Johnson and Johnson
McKesson

Last Updated: October 1, 2022

VERQUVO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Verquvo, and when can generic versions of Verquvo launch?

Verquvo is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are five patents protecting this drug.

This drug has two hundred patent family members in forty-eight countries.

The generic ingredient in VERQUVO is vericiguat. One supplier is listed for this compound. Additional details are available on the vericiguat profile page.

DrugPatentWatch® Generic Entry Outlook for Verquvo

Verquvo will be eligible for patent challenges on January 19, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for VERQUVO
International Patents:200
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 40
Clinical Trials: 1
Patent Applications: 181
Drug Prices: Drug price information for VERQUVO
What excipients (inactive ingredients) are in VERQUVO?VERQUVO excipients list
DailyMed Link:VERQUVO at DailyMed
Drug patent expirations by year for VERQUVO
Drug Prices for VERQUVO

See drug prices for VERQUVO

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VERQUVO
Generic Entry Date for VERQUVO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VERQUVO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Josef StehlikPhase 4
Merck Sharp & Dohme LLCPhase 4

See all VERQUVO clinical trials

Pharmacology for VERQUVO

US Patents and Regulatory Information for VERQUVO

VERQUVO is protected by five US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VERQUVO is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VERQUVO


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Substituted 5-fluoro-1H-pyrazolopyridines and their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Substituted 5-flouro-1H-pyrazolopyridines and their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

FDA Regulatory Exclusivity protecting VERQUVO

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-002 Jan 19, 2021 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VERQUVO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bayer AG Verquvo vericiguat EMEA/H/C/005319
Treatment of symptomatic chronic heart failure
Authorised no no no 2021-07-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for VERQUVO

When does loss-of-exclusivity occur for VERQUVO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 98
Estimated Expiration: See Plans and Pricing

Argentina

Patent: 8983
Estimated Expiration: See Plans and Pricing

Australia

Patent: 12342547
Estimated Expiration: See Plans and Pricing

Patent: 17254916
Estimated Expiration: See Plans and Pricing

Patent: 19202123
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2014012414
Estimated Expiration: See Plans and Pricing

Patent: 2020001312
Estimated Expiration: See Plans and Pricing

Canada

Patent: 56706
Estimated Expiration: See Plans and Pricing

Patent: 40720
Estimated Expiration: See Plans and Pricing

Chile

Patent: 14001339
Estimated Expiration: See Plans and Pricing

Patent: 16000344
Estimated Expiration: See Plans and Pricing

China

Patent: 4159898
Estimated Expiration: See Plans and Pricing

Patent: 5503867
Estimated Expiration: See Plans and Pricing

Patent: 6905314
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 60555
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 140237
Estimated Expiration: See Plans and Pricing

Patent: 190057
Estimated Expiration: See Plans and Pricing

Patent: 210072
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0161501
Estimated Expiration: See Plans and Pricing

Patent: 0181818
Estimated Expiration: See Plans and Pricing

Patent: 0210507
Estimated Expiration: See Plans and Pricing

Cuba

Patent: 257
Estimated Expiration: See Plans and Pricing

Patent: 354
Estimated Expiration: See Plans and Pricing

Patent: 140055
Estimated Expiration: See Plans and Pricing

Patent: 150123
Estimated Expiration: See Plans and Pricing

Patent: 150124
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 82914
Estimated Expiration: See Plans and Pricing

Patent: 96617
Estimated Expiration: See Plans and Pricing

Patent: 21470
Estimated Expiration: See Plans and Pricing

Dominican Republic

Patent: 014000112
Estimated Expiration: See Plans and Pricing

Patent: 017000013
Estimated Expiration: See Plans and Pricing

Patent: 021000179
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 14001627
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 0018
Estimated Expiration: See Plans and Pricing

Patent: 1602
Estimated Expiration: See Plans and Pricing

Patent: 3455
Estimated Expiration: See Plans and Pricing

Patent: 1491028
Estimated Expiration: See Plans and Pricing

Patent: 1690520
Estimated Expiration: See Plans and Pricing

Patent: 1690521
Estimated Expiration: See Plans and Pricing

Patent: 1892050
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 82914
Estimated Expiration: See Plans and Pricing

Patent: 96617
Estimated Expiration: See Plans and Pricing

Patent: 21470
Estimated Expiration: See Plans and Pricing

Guatemala

Patent: 1400101
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 03951
Estimated Expiration: See Plans and Pricing

Patent: 23613
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 31029
Estimated Expiration: See Plans and Pricing

Patent: 41592
Estimated Expiration: See Plans and Pricing

Patent: 53745
Estimated Expiration: See Plans and Pricing

Israel

Patent: 2585
Estimated Expiration: See Plans and Pricing

Patent: 6265
Estimated Expiration: See Plans and Pricing

Patent: 3389
Estimated Expiration: See Plans and Pricing

Japan

Patent: 89315
Estimated Expiration: See Plans and Pricing

Patent: 40391
Estimated Expiration: See Plans and Pricing

Patent: 92436
Estimated Expiration: See Plans and Pricing

Patent: 15502932
Estimated Expiration: See Plans and Pricing

Patent: 17031180
Estimated Expiration: See Plans and Pricing

Patent: 18058860
Estimated Expiration: See Plans and Pricing

Patent: 18199698
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 82914
Estimated Expiration: See Plans and Pricing

Patent: 96617
Estimated Expiration: See Plans and Pricing

Patent: 21470
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 8412
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 7481
Estimated Expiration: See Plans and Pricing

Patent: 14006018
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 718
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 4593
Estimated Expiration: See Plans and Pricing

Patent: 1592
Estimated Expiration: See Plans and Pricing

Patent: 4215
Estimated Expiration: See Plans and Pricing

Peru

Patent: 142359
Estimated Expiration: See Plans and Pricing

Patent: 190180
Estimated Expiration: See Plans and Pricing

Patent: 190181
Estimated Expiration: See Plans and Pricing

Philippines

Patent: 014501160
Estimated Expiration: See Plans and Pricing

Patent: 015501494
Estimated Expiration: See Plans and Pricing

Poland

Patent: 82914
Estimated Expiration: See Plans and Pricing

Patent: 96617
Estimated Expiration: See Plans and Pricing

Patent: 21470
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 82914
Estimated Expiration: See Plans and Pricing

Patent: 96617
Estimated Expiration: See Plans and Pricing

Patent: 21470
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 387
Estimated Expiration: See Plans and Pricing

Patent: 945
Estimated Expiration: See Plans and Pricing

Patent: 609
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201604192X
Estimated Expiration: See Plans and Pricing

Patent: 201604196V
Estimated Expiration: See Plans and Pricing

Patent: 201402111Q
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 82914
Estimated Expiration: See Plans and Pricing

Patent: 96617
Estimated Expiration: See Plans and Pricing

Patent: 21470
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1403613
Estimated Expiration: See Plans and Pricing

Patent: 1505970
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1943788
Estimated Expiration: See Plans and Pricing

Patent: 1993022
Estimated Expiration: See Plans and Pricing

Patent: 2026059
Estimated Expiration: See Plans and Pricing

Patent: 140105483
Estimated Expiration: See Plans and Pricing

Patent: 170130612
Estimated Expiration: See Plans and Pricing

Patent: 190018021
Estimated Expiration: See Plans and Pricing

Spain

Patent: 03028
Estimated Expiration: See Plans and Pricing

Patent: 94158
Estimated Expiration: See Plans and Pricing

Patent: 64009
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 97280
Estimated Expiration: See Plans and Pricing

Patent: 31123
Estimated Expiration: See Plans and Pricing

Patent: 59016
Estimated Expiration: See Plans and Pricing

Patent: 65198
Estimated Expiration: See Plans and Pricing

Patent: 1329076
Estimated Expiration: See Plans and Pricing

Patent: 1708219
Estimated Expiration: See Plans and Pricing

Patent: 1831447
Estimated Expiration: See Plans and Pricing

Patent: 1838993
Estimated Expiration: See Plans and Pricing

Patent: 1932465
Estimated Expiration: See Plans and Pricing

Tunisia

Patent: 14000227
Estimated Expiration: See Plans and Pricing

Turkey

Patent: 1816203
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 6623
Estimated Expiration: See Plans and Pricing

Patent: 9269
Estimated Expiration: See Plans and Pricing

Patent: 0278
Estimated Expiration: See Plans and Pricing

Uruguay

Patent: 467
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VERQUVO around the world.

Country Patent Number Title Estimated Expiration
Slovenia 2576548 See Plans and Pricing
Spain 2603028 See Plans and Pricing
Taiwan I665198 See Plans and Pricing
Portugal 2782914 See Plans and Pricing
African Regional IP Organization (ARIPO) 3898 Method for producing substituted 5-fluoro-1H-pyrazolopyridines See Plans and Pricing
Denmark 3421470 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VERQUVO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2576547 CA 2021 00032 Denmark See Plans and Pricing PRODUCT NAME: VERICIGUAT OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE; REG. NO/DATE: EU/1/21/1561 20210720
2576547 C02576547/01 Switzerland See Plans and Pricing PRODUCT NAME: VERICIGUAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68001 22.09.2021
2576547 2190031-1 Sweden See Plans and Pricing PRODUCT NAME: VERICIGUAT AND ITS SALTS, SOLVATES AND SOLVATES OF THE SALTS; REG. NO/DATE: EU/1/21/1561 20210720
2576547 2021C/553 Belgium See Plans and Pricing PRODUCT NAME: VERICIGUAT EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720
2576547 132021000000137 Italy See Plans and Pricing PRODUCT NAME: VERICIGUAT(VERQUVO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1561, 20210720
2576547 PA2021518 Lithuania See Plans and Pricing PRODUCT NAME: VERICIGUATAS IR JO DRUSKOS, SOLVATAI IR DRUSKU SOLVATAI ; REGISTRATION NO/DATE: EU/1/21/1561 20210716
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
AstraZeneca
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.